Scientific repudiation
Skepticism relating to scotopic sensitivity syndromes exact pathology has evolved on several fronts: 

Whether it exists as a distinct, predictably identifiable disease with a reasonable pathophysiological mechanism, or whether a range of symptoms from other conditions are being placed under this convenient heading;
Whether it is causally or incidentally related to dyslexia, autism, or other conditions; and
Whether existing methods of scotopic sensitivity syndrome treatment are appropriate and effective.A 2009 report by the American Academy of Pediatrics (AAP) does not find that there is conclusive scientific evidence for the use of coloured lenses (one treatment used to relieve symptoms of scotopic sensitivity syndrome) although it acknowledges anecdotal evidence in support of customized colored lenses. When discussing its scientific basis, the AAP mentions that "[t]he method used to select the lens or filter color has been highly variable, the color selection has also shown considerable variability, and the test-retest consistency has been poor" (p. 843). The association of scotopic sensitivity syndrome and dyslexia has been challenged by many authors in the optometric and ophthalmologic communities. Furthermore, many special education departments at universities challenge the validity of coloured lenses as an effective treatment for the condition as outlined by the Macquarie University Special Education Centre. In a joint statement, The American Academy of Ophthalmology, American Academy of Pediatrics, American Association for Pediatric Ophthalmology and Strabismus and American Association of Certified Orthoptists firmly repudiated the use of lenses, stating that there was no scientific evidence supporting their use.
Olanzapine was effective for treating the prodromal symptoms, but was associated with significant weight gain. References
External links

"Olanzapine". Drug Information Portal. U.S. National Library of Medicine. Alex B (5 January 2007). "Lilly Settles With 18,000 Over Zyprexa". The New York Times.